Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OBLN Obalon Therapeutics (OBLN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Obalon Therapeutics Stock (NASDAQ:OBLN) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Obalon Therapeutics alerts:Sign Up Key Stats Today's Range$4.28▼$4.6950-Day Range$2.36▼$7.6452-Week Range$0.66▼$10.77Volume41,464 shsAverage Volume7.68 million shsMarket Capitalization$43.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Read More… Receive OBLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Obalon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OBLN Stock News HeadlinesInterWest Management Partners X, LLC's Net WorthAugust 4, 2024 | benzinga.comObalon Therapeutics, Inc.February 25, 2024 | thestreet.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 22, 2024 | Crypto 101 Media (Ad)Spero Therapeutics Inc.February 6, 2024 | wsj.comIntragastric Balloon Market Growth and Forecast till 2031March 28, 2023 | marketwatch.comIntragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 PagesAugust 17, 2022 | marketwatch.comRenovare Environmental Inc (RENO)January 5, 2022 | investing.comUnderstanding Atara Biotherapeutics's Unusual Options ActivityAugust 10, 2021 | benzinga.comSee More Headlines OBLN Stock Analysis - Frequently Asked Questions How were Obalon Therapeutics' earnings last quarter? Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced its quarterly earnings results on Thursday, March, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.11. The business earned $0.06 million during the quarter. Obalon Therapeutics had a negative net margin of 776.76% and a negative trailing twelve-month return on equity of 161.38%. When did Obalon Therapeutics' stock split? Obalon Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Obalon Therapeutics IPO? Obalon Therapeutics (OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Obalon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Canopy Growth (CGC), Plug Power (PLUG), NIO (NIO), NVIDIA (NVDA) and OPKO Health (OPK). Company Calendar Last Earnings3/11/2021Today12/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:OBLN CUSIPN/A CIK1427570 Webwww.obalon.com Phone(844) 362-2566FaxN/AEmployees2Year Founded2008Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,330,000.00 Net Margins-776.76% Pretax MarginN/A Return on Equity-161.38% Return on Assets-83.58% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.86 Sales & Book Value Annual Sales$1.59 million Price / Sales27.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book7.30Miscellaneous Outstanding Shares10,022,000Free FloatN/AMarket Cap$43.90 million OptionableNot Optionable Beta-1.23 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:OBLN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.